First Bank & Trust Acquires 2,569 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

First Bank & Trust raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,269 shares of the biopharmaceutical company’s stock after buying an additional 2,569 shares during the period. First Bank & Trust’s holdings in Gilead Sciences were worth $2,803,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Etesian Wealth Advisors Inc. lifted its holdings in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares during the last quarter. Financial Counselors Inc. lifted its stake in shares of Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the period. Steph & Co. grew its stake in Gilead Sciences by 1.9% in the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after buying an additional 142 shares during the last quarter. Finally, First Affirmative Financial Network raised its holdings in Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 147 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.22 during trading hours on Friday, reaching $68.61. The company’s stock had a trading volume of 9,590,049 shares, compared to its average volume of 9,497,302. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a market capitalization of $85.48 billion, a price-to-earnings ratio of 190.58, a PEG ratio of 2.93 and a beta of 0.20. The firm’s 50 day simple moving average is $65.98 and its 200-day simple moving average is $72.58.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $1.37 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.49%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GILD shares. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research report on Wednesday, April 24th. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research report on Friday, June 14th. Maxim Group dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Finally, Morgan Stanley decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.